Objective-MicroRNAs are important intracellular regulators of gene expression, but also circulate in the blood being protected by extracellular vesicles, proteins, or high-density lipoprotein (HDL). Here, we evaluate the regulation and potential function of HDL-and low-density lipoprotein-bound miRs isolated from healthy subjects and patients with coronary artery disease. Approach and Results-HDL-bound miRs with known effects in the cardiovascular system were analyzed in HDL isolated from healthy subjects (n=10), patients with stable coronary artery disease (n=10), and patients with an acute coronary syndrome (n=10). In HDL from healthy subjects, miR-223 was detected at concentrations >10 000 copies/µg HDL, and miR-126 and miR-92a at about 3000 copies/µg HDL. Concentrations of most miRs were substantially higher in HDL as compared with low-density lipoprotein. However, HDL-bound miR-223 contributed to only 8% of the total circulating miRs. The signatures of miRs varied only slightly in HDL derived from patients with coronary artery disease. We did not observe a significant uptake of HDL-bound miRs into endothelial cells, smooth muscle cells, or peripheral blood mononuclear cells. However, patient-derived HDL transiently reduced miR expression particularly when incubated with smooth muscle and peripheral blood mononuclear cells. 
M icroRNAs (miRs) are endogenously expressed small noncoding RNAs that regulate gene expression on the posttranscriptional level by degradation or translational repression of target mRNAs. Primary microRNA transcripts (pri-miRs) are processed by the endonucleases Drosha and Dicer into precursor miRs (pre-miRs) and mature miRs. Incorporated into the RNA-induced silencing complex, miRs bind to hundreds of target mRNAs and thereby control gene expression patterns. MiRs exhibit important functions in the cardiovascular system. [1] [2] [3] For example, the endothelialenriched miR-126 controls vascular integrity 4, 5 and provides atheroprotective effects. 6 In contrast, miR-92a blocks blood vessel growth and impairs endothelial cell functions. 7 The miR-143/145 cluster is highly expressed in vascular smooth muscle cells (SMCs) and prevents atherosclerotic lesion formation by influencing vascular SMC phenotypes. [8] [9] [10] Several inflammation-associated miRs have been described, such as miR-146 and miR-155, which might influence the proinflammatory environment and thereby may affect atherosclerotic lesion formation. 11 MiR-targeted therapeutics might become a highly interesting novel approach to treat cardiovascular disease. 12 Although miRs act intracellular, they can be released and detected in circulating blood and might be used as disease biomarkers. 13 MiRs are remarkably stable in plasma indicating that they are protected from RNase-dependent degradation. Several studies showed that miRs are protected by lipid vesicles or protein conjugates. [14] [15] [16] MiRs are actively secreted in microvesicles, 17, 18 contained in apoptotic bodies 6 or bound to proteins like Argonaute2. 16 Interestingly, endothelial cell-derived apoptotic bodies were shown to contain high levels of miR-126 and reduce atherosclerosis when injected in mice models. 6 Likewise, microvesicles derived from flowexposed endothelial cells are enriched in atheroprotective miRs and inhibit atherosclerotic lesion formation in ApoE to hepatocytes. 14 The functional properties of miRs that are bound to HDL in the cardiovascular system, however, are unclear.
Elevated HDL cholesterol level is associated with reduced risk for coronary artery disease (CAD), and HDL from healthy subjects (HS) has been shown to exert potential atheroprotective effects by several mechanisms. However, HDL-raising therapy using cholesteryester transfer protein inhibitors, torcetrapib or dalcetrapib, has failed to reduce cardiovascular events in patients with coronary disease so far, which may in part be related to different vascular effects of HDL from patients with CAD as compared with HDL from HS. 20 In the present study, we addressed whether circulating HDL and also low-density lipoprotein (LDL) contain miRs implicated in cardiovascular disease and may control vascular functions by delivering miRs. Second, we analyzed HDL-bound miRs in patients with stable CAD and acute coronary syndrome (ACS) as compared with HDL from HS to determine whether the miR signature of HDL is different in patients with coronary disease. Because of the limited amount of RNA we could derive from plasma HDL, we focused our analysis on a subset of vascular and inflammation-associated miRs-miR92a, miR-126, miR-150, and miR-378-which are highly expressed in endothelial cells and regulate angiogenesis, 5, 7, 21 the smooth muscle-specific miR-145, which is the most abundant miR in the vascular wall, 22 miR-30c that is highly expressed in cardiac myocytes 23 but is also enriched in endothelial cells, and miR-146a and miR-155, which are involved in the control of inflammation-associated processes. 24, 25 MiR-223 is enriched in the liver and was shown to be bound to HDL in a previous study.
14 Among the miRs tested, particularly miR-145 and miR-150 were shown to be released from cells in microvesicles. 19, 26 Here, we demonstrate that miRs known to be relevant in the cardiovascular system are bound to HDL albeit at low copy numbers but are not transferred to endothelial, SMCs, and peripheral blood mononuclear cells (PBMCs) in vitro.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Quantification of Human HDL and LDL Containing microRNAs
First, we determined whether vascular and inflammationassociated miRNAs are bound to HDL and LDL at biologically relevant concentrations. HDL and LDL were isolated from HS (n=10 for HDL; n=5 for LDL), and miRs were detected by quantitative real-time polymerase chain reaction using recombinant miRs for quantification. Consistent with previous findings, miR-223 was highly bound to HDL at concentrations of >10 000 copies/µg HDL ( Figure 1A) . The endothelial-enriched miR-126 was detected in HDL with ≈2800 copies/µg HDL. Likewise, miR-92a, which is highly expressed in endothelial cells, was detected in HDL at a similar concentration ( Figure 1A ). MiR-150, which is released by monocytes and controls endothelial cell migration, 26 was detected albeit at a lower level. The smooth muscle-enriched miR-145, inflammation-associated miRs, such as miR-146a and miR-155, and the metabolically controlled miR-378 were detected at levels <120 copies/µg HDL ( Figure 1A) .
Next, we determined the miR concentrations bound to LDL. Similar to HDL, miR-223 is also of the most abundant miRs in LDL. However, only 1500 copies/µg LDL as compared with >10 000 copies/µg HDL miR-223 were detected ( Figure 1A ). The concentrations of LDL-bound miR-126, miR-145, miR-150, miR-378, and miR-30c were extremely low (<10 copies/µg LDL). In contrast, the proatherosclerotic miR-155 is more highly abundant in LDL as compared with HDL ( Figure 1A) .
Furthermore, we examined to what extent HDL-bound miRs contribute to the total pool of circulating miRs. Therefore, we measured the miR concentrations in the total plasma of the same individuals from whom HDL was isolated ( Figure 1B ) and calculated the percentage of HDL-associated miRs compared with the total plasma concentrations. HDL-bound miR-223 contributes to ≈8% of the total plasma pool ( Figure 1C ). About 4% to 5% of circulating miR-126 and miR-378 were associated with HDL, whereas 1% to 2% miR-92a and miR-150 and <1% of the other miRs were HDL-bound ( Figure  1C ). Overall, there is a highly significant correlation between the absolute concentrations of miRs bound to HDL and the corresponding concentrations of miRs in plasma ( Figure 1D ). However, some miRs (eg, miR-223, miR-146a) varied only in the plasma fraction independently of the concentrations in HDL, whereas others (miR-155, miR-92a, miR-150) differed in the HDL fraction and were more constant in plasma ( Figure 1D ).
HDL-and LDL-miR Signatures in Patients With Coronary Disease
HDL derived from patients with coronary disease shows a significantly impaired vasculoprotective function. 27 Therefore, we examined whether miR signatures might be different in HDL isolated from these patients. HDL was isolated from patients with stable CAD (n=10) and patients with an ACS (n=10; for patient characteristics see Table I in the online-only Data Supplement). MiR levels in HDL isolated from patients with stable CAD did not significantly differ from those measured in HDL derived from HS. In contrast, in patients with ACS, the absolute copy numbers of HDL-bound miR-92a, miR-146, and miR-30c were significantly reduced as compared with the miR concentrations measured in HDL derived from HS ( Figure 2A ).
In LDL, no significant differences in miR levels isolated from HS and patients with CAD and ACS could be detected ( Figure I in the online-only Data Supplement). To determine whether there is a change in the distribution of circulating miRs in patients with coronary disease, we additionally measured the miR concentrations in plasma of the same patients and calculated the percentage of HDL-bound miRs in total plasma. Overall, also in patients with coronary disease HDL-bound miRs correlated with the total miR concentrations in the plasma ( Figure II in the online-only Data Supplement), but we observed that the percentage of HDL-bound miR-92a was reduced in patients with CAD and ACS ( Figure 2B) . Moreover, the level of HDL-bound miR-155 was significantly increased in patients with ACS but generally was very low (<0.5%; Figure 2B ). All other analyzed HDL-bound miRs showed no significant differences between healthy controls and patients with CAD.
Transfer of HDL-Bound miRs to Cultured Endothelial Cells
Previous studies have suggested that HDL-bound miRs can be transferred to SRBI overexpressing baby hamster kidney cells and hepatocytes.
14 Therefore, we examined whether HDL might also deliver miRs to endothelial cells.
Because HDL might influence the biosynthesis and processing of endogenously expressed miRs in endothelial cells, we incorporated an artificial Caenorhabditis elegans miR (cel-miR-39) in HDL in vitro. After removal of unbound miRs, we determined the uptake in human umbilical venous endothelial cells ( Figure 3A) . We analyzed the uptake of the mature single-stranded cel-miR-39, as well as 2 different double-stranded precursor miRs, cel-miR-39 mimic, and cel-miR-39 pre-miR (cel-pre-miR-39). Only ≈5 copies HDLbound mature cel-miR-39 and cel-miR-39 mimic were taken up per cell, whereas free mature miRs, which were not bound to HDL did not enter the cells ( Figure 3B ). HDL-bound celmiR-39 precursor was taken up by endothelial cells in similar amounts, but in contrast higher levels (≈50 copies per cell) of HDL-free cel-pre-miR-39 were incorporated in the cells ( Figure 3B) .
Together these data demonstrate that HDL-bound synthetic miRs can be transferred to cultured endothelial cells; however, only very low copy numbers were detected in the recipient cells. 
Effect of HDL on miR Expression in Different Cell Types
Next we analyzed whether endogenous HDL-bound miRs can be delivered to endothelial cells (human umbilical venous endothelial cells), SMC, and PBMC. We incubated human umbilical venous endothelial cells (HUVECs), SMCs, and PBMCs with HDL and measured the expression of those miRs, which were associated with HDL at concentrations >2000 copies/µg HDL, namely miR-223, miR-92a, and miR-126 ( Figure 1A ). All 3 analyzed miRs were slightly reduced in HUVECs after 1 hour incubation with HDL ( Figure 3D ). Even miR-223, which is highly bound to HDL and very lowly expressed in cultured endothelial cells (cycle threshold=30), but induces angiogenesis if overexpressed in cultured endothelial cells ( Figure III in the online-only Data Supplement), was not transferred to endothelial cells ( Figure 3D ). Furthermore, increasing the HDL concentration to 1 mg/mL and extending the incubation time to 24 hours did not increase the levels of miR-126, miR-92a, and miR-223 in endothelial cells ( Figure  IV in the online-only Data Supplement).
In SMCs, miR-92a and miR-126 were also transiently reduced after 1 hour ( Figure 3E ). miR-223 was very lowly expressed in SMCs (cycle threshold=28), and its expression was not significantly changed after HDL treatment ( Figure  3E ). HDL incubation for 1 or 6 hours reduced miR levels in PBMCs ( Figure 3F ). In summary, no significant transfer of native HDL-bound miRs to endothelial, smooth muscle, or mononuclear cells could be documented. In contrast, HDL from HS overall tends to reduce the endogenous levels of the measured miRs in all analyzed cell types.
Effects of HDL From Patients With Coronary Disease on Different Cell Types
Next we studied the effect of HDL derived from patients with coronary disease on miR expression in the different cell types. Similar to HDL from HS, HDL from patients with stable CAD or ACS had no significant effect on miR expression in endothelial cells ( Figure 4A ). HDL from patients with CAD or ACS also slightly reduced the expression levels of miR-92a and miR-126 in SMCs, whereas miR-223 levels were unaffected ( Figure 4B ). In PBMCs, miR expression was significantly decreased by 40% to 50% 1 hour after incubation with HDL from patients with coronary disease ( Figure 4C ). However, the decrease was only transient, and miR levels were increased at 6 hours after incubation of PBMCs with HDL from patients with coronary disease ( Figure 4C ).
Influence of HDL on miR Biogenesis in PBMCs
Because the most profound effect on miR expression change was observed when incubating PBMCs with HDL, we sought to elucidate the mechanism by which HDL influences endogenous miR levels. Therefore, we determined the expression levels of primary (pri-) and precursor (pre-) miRs and mRNA levels of Drosha and Dicer, the enzymes responsible for miR processing after treatment with HDL from HS and HDL from patients with coronary disease ( Figure 5) .
HDL had no effect on pri-and pre-miR-92a and miR-223 ( Figure 5A ). In contrast, pri-and pre-miR-126 levels were significantly reduced after 1 hour and increased after 6 hours of HDL treatment, with similar kinetics as shown before for the mature miR-126 levels ( Figures 4C and 5A ). Drosha and Dicer expression were not altered in PBMCs by HDL treatment ( Figure 5B) . In endothelial cells, no change in primiRs, pre-miRs, Drosha, and Dicer expression was detected up to 100 µg HDL/mL ( Figure In summary, our data suggest that HDL has an effect on miR-126 transcription, whereas miR-92a and miR-223 levels are regulated by posttranscriptional mechanisms.
Discussion
The present study examines for the first time HDL-associated vascular and inflammatory miRs in HS and in patients with stable CAD or ACS and elucidates to what extent HDL-miRs are transferred to endothelial cells. Moreover, we investigated the effects of HDL from HS and patients with coronary disease on miR levels that are relevant in the cardiovascular system in endothelial cells, SMCs, and PBMCs.
We demonstrate that miR-223, miR-92a, and miR-126 were found at highest concentrations in HDL, whereas all other miRs tested were <500 copy numbers/µg HDL. HDL consists of a large amount of different HDL-bound molecules, including proteins, lipids, and small molecules. Therefore, we have to consider that likely not all HDL-bound molecules are binding miRs. However, our finding that miR-223 was the most abundant miR (≈10 000 copies/µg HDL) is consistent with the study of Vickers et al, 14 showing that this miR is strongly enriched in purified HDL. Overall, the concentration of HDL-miRs strongly correlated to the total plasma pool of circulating miRs raising the question of whether the presence of miRs in HDL might reflect unspecific binding to circulating miRs in the plasma. However, when calculating the percentage of HDL-miRs to the total pool of circulating miRs, we observed that some miRs, such as miR-126, miR-378, and miR-223, were more efficiently bound to HDL as compared with other miRs (Figure 1D ), suggesting some specificity of the miR-binding. The maximal levels, however, are still <10% of the respective plasma miR levels suggesting that the majority of circulating miRs is not associated with HDL.
Moreover, we analyzed to what extent miRs are also associated with LDL and whether this is altered in patients with coronary disease. LDL has been shown to carry a different composition of miRs compared with HDL 14 and does not exhibit similar functions, for instance LDL is not able to activate endothelial nitric oxide synthase. 28 Similar to HDL, miR-223 is also the most abundant miR in LDL, but is reduced by 7-fold compared with HDL. Interestingly the only miR that is more highly bound to LDL compared with HDL is miR-155 (177 copies/µg LDL versus 44 copies/µg HDL). MiR-155 promotes atherosclerosis and is specifically expressed in atherosclerotic plaques and proinflammatory macrophages. 29 Furthermore, LDL induces miR-155 expression in macrophages 29 indicating a possible transfer of LDL-bound miR-155 to macrophages and atherosclerotic plaques.
Our data further demonstrate that HDL-miRs are not efficiently taken up by endothelial cells. To determine the direct transfer of HDL-miRs to endothelial cells, we loaded HDL with recombinant C. elegans miRs and incubated these HDLmiR complexes with endothelial cells in vitro. We indeed detected the presence of C. elegans miRs in endothelial cells; however, the copy numbers are very low (<10 copies per cell). In lymphocytes, endogenous miRs were shown to be expressed at 5000 to 33 000 copies per cell. 30 MiR-126 and miR-92a were found to be expressed in a similar range in our study (data not shown) suggesting that the low number of copies that are transferred by HDL are unlikely to have any significant biological function. Previous studies demonstrated that HDL delivers exogenous or endogenous miRs to SRBI expressing baby hamster kidney cells and hepatocytes, which are known to efficiently take up lipoproteins and oligonucleotides. 31 Endothelial cells were shown to express the SRBI receptor, 32 but seem less sensitive for the uptake of HDL-bound miRs in our setting. In contrast, endothelial cells were shown to efficiently take up microvesicle-embedded miRs. 6, 19 Of note, we cannot exclude that differences in the HDL-preparations (eg, Vickers et al 14 used recombinant HDL which was made free of RNA before loading) may have influence on the results. However, we controlled the loading of the HDL with C. elegans miRs (1×10 7 to 6×10 9 copies/µg HDL), and the incubation of endothelial cells with high concentrations of native HDL (up to 1 mg/mL) also did not increase the endogenous miRs in the cultured endothelial cells ( Figure IV in the online-only Data Supplement).
In contrast, our data rather suggest that native HDL can transiently reduce the expression of miR-92a, miR-126, and miR-223. The HDL-induced transient reduction of miRs was also observed in SMCs, and a continuous decline of miR expression was detected in PBMCs. In addition, our data demonstrate that LDL did not increase the expression of the endothelial miRs suggesting that LDL-bound miRs, which were detected at even lower concentrations compared with HDL, are not efficiently transferred ( Figure Previous studies demonstrated that familial hypercholesterolemia is associated with a distinct HDL-miR pattern as compared with normal subjects 14 ; however, the impact of coronary disease has not been explored. Therefore, we analyzed the miR profile of HDL that was purified from patients with stable CAD or ACS. Indeed, some miRs were significantly regulated in HDL from patients with CAD as compared with normal subjects. HDL-bound miR-92a was most profoundly reduced in stable CAD and ACS. Moreover, the inflammation-associated miR-146a and miR-30c, whose function is unknown, were slightly but significantly downregulated in HDL from ACS patients. Because no significant changes of LDL-bound miRs were observed in patient-derived LDL as compared with LDL from HS, LDLmiR pattern is likely not altered in coronary disease. However, when incubating patient-derived HDL with endothelial cells, the transient reduction of endothelial miR levels induced by HDL from HS was abrogated. On the contrary, in SMCs and PBMCs the transient reduction in endogenous miR expression caused by HDL from HS was even further intensified with patient-derived HDL. Surprisingly, in PBMCs the endogenous expression of miR-92a, miR-126, and miR-223 was increased after longer incubation with HDL derived from patients with stable CAD or ACS, in contrast to the effect of HDL from HS which reduced the expression of these miRs. The different cellular responses to HDL derived from healthy controls versus patients with CAD are in line with previous studies suggesting that a different biological activity of CAD patient versus healthy control-derived HDL can be observed for several cellular functions. 33 The rapid time course of miR expression changes suggests that HDL influences the turn over or processing of miRs. However, the downregulation of miR-126 levels after 1 hour of HDL incubation seems to be primarily influenced by a reduced expression of the pri-miR-126 suggesting that HDL rapidly either blocks transcription or destabilizes the pri-miR-126. In contrast, primary and precursor of miR-92 and miR-223 were not influenced. These data indicate that reduction of miR-92a and miR-223 may be either because of a block of Dicer processing or a destabilization of the mature miR. An interesting alternative hypothesis to explain these findings may be that HDL removes miRs from cells. It is well known that HDL can be transported through endothelial cells 34 and can export lipids from atherosclerotic plaques, a process known as reverse cholesterol export. 35 Together, our data confirm that miRs are transported in plasma by HDL and to a lesser extent also by LDL. The contribution of HDL-bound miR to the total miR pool, however, is rather low. The HDL-bound miRs were not efficiently delivered to endothelial cells, SMCs, and PBMCs suggesting that the HDL-associated pool of miRs may not be of a major importance for the regulation of the biological functions in these cells. However, the present data do not exclude that HDL-bound miRs may be taken up in vivo, for instance, in atherosclerotic lesions or foam cells.
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